Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Axogen Inc (AXGN) vs Jabil Inc (JBL) Price & Performance

Axogen IncTrade

Price performance (Past 24H)

Key statistics

Axogen Inc vs Jabil Inc — how do they compare? Axogen Inc trades at $48.35 (market cap $2.61B), while Jabil Inc trades at $362 (market cap $37.37B). The key difference: Jabil Inc is far larger — about 14.3× Axogen Inc's market cap, and Jabil Inc pays a 0.09% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.

AXGNJBL
Market Cap
$2.61B$37.37B
Sector
TechnologyTechnology
52-Week High
$48.48$385.50
52-Week Low
$14.16$192.49
Enterprise Value
$2.52B$39.90B
Dividend Yield
0.09%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Axogen Inc

AXGN is trading at $46.43, up 4.69% today, with strong technical momentum and bullish moving average signals. The company reported Q2 2026 revenue growth of 23.1% to $69.7 million and raised full-year guidance to at least $279 million. Despite recent earnings misses, analyst sentiment remains overwhelmingly positive with 84% buy ratings and a $54.33 price target.

The stock presents growth potential driven by expanding nerve care platform adoption and reimbursement improvements, but faces risks from persistent net losses (-$15.7M in 2025) and high valuation multiples (P/S 9.5). Near-term performance hinges on Q3 earnings delivery and continued commercial execution amid competitive pressures.

Jabil Inc

Jabil trades at $341.22, down 1.0% today but maintains strong momentum with a bullish technical outlook and consistent earnings beats. The stock shows robust fundamentals with revenue growth from $29.8B in 2025 to $33.6B projected for 2026, supported by AI infrastructure demand and diversified operations. Recent news highlights Jabil's 31.6% six-month surge and strategic expansion with a new logistics hub in Penang.

Jabil presents a compelling growth story driven by AI and manufacturing excellence, with analyst consensus pointing to significant upside (target $448.29). However, elevated valuation multiples (P/E 42.13) and competitive pressures in the EMS sector warrant caution. The stock's technical strength and fundamental momentum support a positive outlook, though investors should monitor execution risks and market volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Axogen Inc

Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.

Read more on AXGN

About Jabil Inc

Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.

Read more on JBL